If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

The immunotherapy used in the trial was nivolumab ( Opdivo ), a drug delivered intravenously that works by disabling a ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

Solid tumors that originate in the deep internal organs, such as the pancreas, liver, and ovary, have poor prognoses due to the difficulties of diagnosing ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

Congratulations to Vivek Malik who was named a Regeneron Science Talent Search 2025 finalist. Vivek is a student at The ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

A group of scientists in China has revealed a novel mechanism whereby a short form of IL-18, generated by caspase-3 cleavage ...